2seventy Bio and JW Therapeutics to expand therapy R&D partnership

2seventy Bio and JW Therapeutics announced their intention to expand their strategic alliance. The expansion, based on the partnership that was established last year, builds upon the companies’ translational and clinical cell therapy development platform originally designed to more rapidly explore T cell-based immunotherapy therapy products in Greater China. Specifically, the companies intend to add up to two additional candidates from the 2seventy portfolio, one in solid tumor indications using T-cell receptor based technology and a second in autoimmune disease using a CAR T cell approach. JW Therapeutics has successfully progressed this candidate and is on track to initiate an investigator-initiated study in China by the end of 2023.